(MedPage Today) — The tau-targeting agent diranersen did not meet the primary endpoint of the phase II CELIA trial, but that isn’t stopping the drug from moving forward.
The placebo-controlled study is the first to show a cognitive benefit and…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
